IMP761 was well tolerated in healthy volunteers when given at single increasing doses, with no safety concerns, according to ...

The ACP received funding to help interpret research and support decisions about MS treatments for older adults with MS.

Advances in diagnostics and disease-modifying therapies have significantly expanded treatment options for MS over the past 2 decades. With more than 20 FDA-approved therapies now available, clinicians ...

A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...

NEW YORK, NY, UNITED STATES, March 24, 2026 /EINPresswire.com/ — Scientists at the Tisch Multiple Sclerosis Research Center ...

March is National Multiple Sclerosis Month, a time to raise awareness about the neurological disease that affects more than ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

For the last 20 years, people have been coming together across the Capital Region to support the National MS Society, while ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...